Matthias Kretzler
Nephrology · Ann Arbor, MINPI 1710990916
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $57,046 of the $70,309 with a category attached, or 81.1%. 13 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 29.0% of the total. Reporting peaked in 2024 at $17,423 and has fallen 53.5% since, to $8,106 in 2025. Among nephrology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $789.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$20K
- Novo Nordisk AS$11K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
- Regeneron$6K
- Gilead$6K
- Janssen Research & Development, LLC$6K
- plus $10K from 7 others
Across 40 payments — averaging $192,189 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.9M
- Travere Therapeutics, Inc.$1.8M
- Astrazeneca AB$894K
- F. Hoffmann-la Roche AG$796K
- Gilead$775K
- Regeneron$505K
- plus $1M from 6 others
What the payments were for
- Consulting fees$57,04681%
- Speaking & faculty fees$1,3252%
- Travel & lodging$9,15513%
- Food & beverage$2,7834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 16 | $20,398 |
| Novo Nordisk AS | 7 | $10,795 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $10,361 |
| Regeneron | 11 | $6,268 |
| Gilead | 6 | $6,088 |
| Janssen Research & Development, LLC | 1 | $6,000 |
| Novartis | 6 | $5,997 |
| Travere Therapeutics, Inc. | 20 | $3,923 |
| Astrazeneca UK Limited | 4 | $143 |
| Apellis Pharmaceuticals, Inc. | 1 | $139 |
| Novo Nordisk US Research & Development, Inc. | 5 | $135 |
| Boehringer Ingelheim | 1 | $44 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$3,520
How this compares
$70,309 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.
Other nephrology in Ann Arbor
- Alexander YevzlinAnn Arbor$1.1M
- Laura MarianiAnn Arbor$150K
- Lenar YessayanAnn Arbor$40K
- Bruce RobinsonAnn Arbor$38K
- Karthik RamaniAnn Arbor$27K
- Rajiv SaranAnn Arbor$23K
- Panduranga RaoAnn Arbor$20K
- Andrea OliverioAnn Arbor$15K
- Abhijit NaikAnn Arbor$10K
- Akinlolu OjoAnn Arbor$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.